Literature DB >> 25361657

Otilonium bromide as spasmolytic during endoscopic retrograde cholangiopancreatography.

Ömer Karahan1, Barış Sevinç, Ahmet Okuş, Serden Ay, Nergis Aksoy.   

Abstract

BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) is commonly used in both the diagnosis and the treatment of biliary and pancreatic disorders. The aim of this study is to evaluate the effects of OB usage during ERCP on duodenal motility, the tolerability of the procedure (by patients) and the difficulty of the procedure (by the endoscopist).
METHOD: The study was conducted in Konya Training and Research Hospital General Surgery Endoscopy Unit in randomized prospective pattern. The patients were divided into the two groups as spasmolytic and control groups. The procedure was performed under topical anesthesia and sedation.
RESULTS: There were 100 cases included into the study (50 cases in each group). The mean duodenal motility score was found to be 1.9 ± 0.5 in the study group and 3 ± 0.6 in the control group. In the study group, the tolerability of the procedure score by the endoscopist was moderate in 16 % and well/very well in 78 % of the cases. On the other hand, in the control group, the scores were poor in 21 %, moderate in 71 %, and well/very well in 24 % of the cases. In terms of patient satisfaction, in study group 42 % of the cases reported the procedure as moderate and 58 % reported as well/very well. However, in the control group 16 % of the cases reported the procedure as poor, 58 % moderate, and 26 % as well/very well.
CONCLUSION: Otilonium bromide is a safe agent with low side effects. It can be used before the ERCP procedure to decrease the duodenal motility. It eases the procedure, moreover, it increases the patients' satisfaction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25361657     DOI: 10.1007/s00464-014-3939-2

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  12 in total

1.  The clinical pharmacology of single doses of otilonium bromide in healthy volunteers.

Authors:  J A Sutton; S G Kilminster; G P Mould
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 2.  Preparation, premedication, and surveillance.

Authors:  M Lazzaroni; G Bianchi Porro
Journal:  Endoscopy       Date:  2001-02       Impact factor: 10.093

3.  Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle.

Authors:  P R Strege; S Evangelista; G L Lyford; M G Sarr; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2004-04       Impact factor: 3.598

Review 4.  Otilonium bromide: a selective spasmolytic for the gastrointestinal tract.

Authors:  S Evangelista
Journal:  J Int Med Res       Date:  1999 Sep-Oct       Impact factor: 1.671

5.  Efficacy of peppermint oil as an antispasmodic during endoscopic retrograde cholangiopancreatography.

Authors:  Natsuyo Yamamoto; Yousuke Nakai; Naoki Sasahira; Kenji Hirano; Takeshi Tsujino; Hiroyuki Isayama; Yutaka Komatsu; Minoru Tada; Mimoru Tada; Haruhiko Yoshida; Takao Kawabe; Naoki Hiki; Michio Kaminishi; Hanzo Kurosaka; Masao Omata
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

6.  [Use of spasmolytic agent otilonium bromide (spasmomen) in digestive endoscopy: a prospective study in 63 patients].

Authors:  N A Gómez; C J León; J Gutiérrez
Journal:  Acta Gastroenterol Latinoam       Date:  1997

Review 7.  Premedication, preparation, and surveillance.

Authors:  G D Bell
Journal:  Endoscopy       Date:  2000-02       Impact factor: 10.093

8.  Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.

Authors:  G Battaglia; A M Morselli-Labate; E Camarri; A Francavilla; F De Marco; G Mastropaolo; R Naccarato
Journal:  Aliment Pharmacol Ther       Date:  1998-10       Impact factor: 8.171

9.  Sublingual L-hyoscyamine for duodenal antimotility during ERCP: a prospective randomized double-blinded study.

Authors:  Christopher R Lynch; Suresh Khandekar; Scott M Lynch; James A Disario
Journal:  Gastrointest Endosc       Date:  2007-10       Impact factor: 9.427

10.  Buscopan or glucagon for endoscopic cannulation of ampulla of vater?

Authors:  B F Hannigan; A T Axon; S Avery; R P Thompson
Journal:  J R Soc Med       Date:  1982-01       Impact factor: 18.000

View more
  1 in total

1.  The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial.

Authors:  Hassan Salmanroghani; Massoud Mirvakili; Mahtabalsadat Mirjalili; Mahmud Baghbanian; Roham Salmanroghani
Journal:  Clin Pharmacol       Date:  2020-08-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.